FDA Approves Belzutifan for Pheochromocytoma or Paraganglioma By Ogkologos - June 6, 2025 778 0 Facebook Twitter Google+ Pinterest WhatsApp Evidence for efficacy is based on the results from the LITESPARK-015 study Source RELATED ARTICLESMORE FROM AUTHOR Comprehensive Genomic Profiling with Subsequent Molecularly Guided Therapy Improves Outcomes Over Platinum-based Chemotherapy in Previously Untreated, Unfavourable CUP NCI and CRUK Take on Cancer’s Toughest Problems Tebentafusp Continues to Provide Long-Term OS Benefit in Previously Untreated Patients with Unresectable or Metastatic Uveal Melanoma MOST POPULAR FDA Grants Accelerated Approval to Encorafenib with Cetuximab and mFOLFOX6 for... January 24, 2025 Many Breast Cancer Patients Use Cannabis to Manage Symptoms But Don’t... October 15, 2021 One year on: How has COVID-19 affected cancer services? May 14, 2021 Cemiplimab Outperforms Investigator’s Choice Chemotherapy in the Second-Line Setting for Recurrent/Metastatic... May 12, 2021 Load more HOT NEWS ESMO-WHO Collaboration in Kazakhstan Yields Evidence-Based Approach for Closing the Gaps... Cell Therapy Improves Progression-Free Survival in Advanced Melanoma, First Phase 3... New insights on self-sampling for cervical cancer screening Exceptional Response Rates and Survival Among Patients with POLE/D1 Proofreading Deficient...
